1-苄基-5-溴吡啶-2(1H)-酮 | 217448-53-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-苄基-5-溴吡啶-2(1H)-酮
• 英文名称: 1-benzyl-5-bromopyridin-2(1H)-one
• 英文别名: 1-benzyl-5-bromo-1,2-dihydropyridin-2-one；1-benzyl-5-bromopyridin-2-one
• CAS: 217448-53-8
• 化学式: C₁₂H₁₀BrNO
• mdl: MFCD02326300
• 分子量: 264.121
• InChiKey: CTTIPOGAOKXCDF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-苄基-5-溴吡啶-2(1H)-酮 在 四(三苯基膦)钯 7-Br-2-Bn-3-oxo-2-aza-6-exo-MeO₂C-bicyclo[2.2.2]oct-7-ene 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 二氯甲烷 为溶剂， 反应 245.0h， 生成 2-benzyl-7-phenyl-(5-endo)-carbomethoxy-3-oxo-2-azabicyclo[2.2.2]oct-7-ene
  参考文献：
  名称：

  Ibogaine analogues. Synthesis and preliminary pharmacological evaluation of 7-heteroaryl-2-azabicyclo[2.2.2]oct-7-enes

  摘要：

  Synthesis of 7-heteroaryl-2-azabicyclo[2.2.2]oct-7-enes by cycloaddition and subsequent cross-coupling reaction is described. Binding affinity of these novel compounds towards the characteristic receptorial targets of ibogaine is illustrated. (C) 2002 Elsevier Science Lid. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00524-2
• 作为产物：
  描述：

  1-苄基1,2-二氢吡啶-2-酮 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.33h， 以47%的产率得到1-苄基-5-溴吡啶-2(1H)-酮
  参考文献：
  名称：

  Ibogaine analogues. Synthesis and preliminary pharmacological evaluation of 7-heteroaryl-2-azabicyclo[2.2.2]oct-7-enes

  摘要：

  Synthesis of 7-heteroaryl-2-azabicyclo[2.2.2]oct-7-enes by cycloaddition and subsequent cross-coupling reaction is described. Binding affinity of these novel compounds towards the characteristic receptorial targets of ibogaine is illustrated. (C) 2002 Elsevier Science Lid. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00524-2

文献信息

• [EN] AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'AMINOPYRIDINE UTILISÉS EN TANT QU'INHIBITEURS DE LA PHOSPHATIDYLINOSITOL PHOSPHATE KINASE
  申请人：PETRA PHARMA CORP

  公开号：WO2019126731A1

  公开（公告）日：2019-06-27

  The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: (I) where A, B, R1, X1, X2, and W are described herein.

  这项发明涉及PI5P4K抑制剂，用于治疗癌症、神经退行性疾病、炎症性疾病和代谢性疾病，其化学式为：(I)，其中A、B、R1、X1、X2和W如本文所述。
• Regioselective N‐Functionalization of Tautomerizable Heterocycles through Methyl Trifluoromethanesulfonate‐Catalyzed Substitution of Alcohols and Alkyl Group Migrations
  作者：Surajit Duari、Subrata Biswas、Arnab Roy、Srabani Maity、Abhishek Kumar Mishra、Aguinaldo R. Souza、Asma M. Elsharif、Nelson H. Morgon、Srijit Biswas

  DOI：10.1002/adsc.202101196

  日期：2022.2.15

  (MeOTf) was found to catalyze the reaction, which revealed the catalytic property of MeOTf. A mechanism was established through experiments as well as DFT calculations wherein the −OH group of alcohols were converted to the corresponding −OMe groups and in situ generated TfOH. The −OMe groups produced underwent TfOH catalyzed −X alkylation (X=O, S) of the heterocycles followed by −X- to −N-alkyl group

  已经开发了一种催化合成策略，结合了两种方案，例如醇的直接亲核取代，然后是X - 到N - 烷基迁移 ( X = O , S ) 以获得N - 官能化苯并恶唑酮、苯并噻唑硫酮、吲哚啉酮、苯并咪唑硫酮和吡啶酮衍生物。发现三氟甲磺酸甲酯 (MeOTf) 可催化该反应，这揭示了 MeOTf 的催化性能。通过实验和 DFT 计算建立了一种机制，其中醇的 -OH 基团原位转化为相应的 -OMe 基团生成 TfOH。产生的 -OMe 基团经历了 TfOH 催化的杂环的 - X烷基化（X = O，S），然后在一个步骤中进行 - X-到 - N-烷基迁移。
• [EN] PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDONE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE KINASE
  申请人：SELVITA S A

  公开号：WO2017068064A1

  公开（公告）日：2017-04-27

  Disclosed in the present application is a compound of formula (I) as defined herein as well as a pharmaceutical composition comprising said compound. Further disclosed in the present application is the use of such pharmaceutical compositions for treating diseases, namely inter alia for use in the treatment of cancer, metabolic, inflammatory, autoimmune and viral diseases. The compounds disclosed herein are inhibitors of MNK1 and/or MNK2 kinases.

  本申请公开了一种如下所定义的化合物（I）以及包含该化合物的药物组合物。本申请还公开了利用这种药物组合物治疗疾病的用途，包括但不限于用于治疗癌症、代谢性疾病、炎症性疾病、自身免疫疾病和病毒性疾病。本文所披露的化合物是MNK1和/或MNK2激酶的抑制剂。
• Novel Heterocyclic Compounds as Bromodomain Inhibitors
  申请人：Liu Shuang

  公开号：US20140179648A1

  公开（公告）日：2014-06-26

  The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.

  本公开涉及一些化合物，这些化合物通过结合溴结构域对BET蛋白功能进行抑制，并且它们在治疗中的应用。
• Iron‐Catalyzed Reactions of 2‐Pyridone Derivatives: 1,6‐Addition and Formal Ring Opening/Cross Coupling
  作者：Lin Huang、Yiting Gu、Alois Fürstner

  DOI：10.1002/asia.201900865

  日期：2019.11.18

  In the presence of simple iron salts, 2-pyridone derivatives react with Grignard reagents under mild conditions to give the corresponding 1,6-addition products; if the reaction medium is supplemented with an aprotic dipolar cosolvent after the actual addition step, the intermediates primarily formed succumb to ring opening, giving rise to non-thermodynamic Z,E-configured dienoic acid amide derivatives

  在简单的铁盐存在下，2-吡啶酮衍生物在温和的条件下与格氏试剂反应，生成相应的1,6-加成产物。如果在实际添加步骤之后向反应介质中添加了质子惰性的偶极助溶剂，则中间体主要形成屈服开环，从而导致非热力学的Z，E构型的二烯酰胺衍生物，否则很难制备。对照实验以及（三羰基）铁吡啶酮配合物的分离和晶体学表征表明，原位生成的活性铁催化剂对嵌入基质杂环系统中的极化二烯系统表现出高亲和力，这很可能是因为实际识别元素。